InterVenn Biosciences Welcomes Accomplished Diagnostics Executive Joshua Stahl as CEO

Stahl will leverage proven experience in building innovative diagnostic organizations to accelerate InterVenn’s commercialization efforts

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- InterVenn Biosciences, the life sciences company pioneering glycoproteomic-based diagnostics, today announced that Joshua Stahl has been appointed as Chief Executive Officer to guide the company’s next phase of commercial growth.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927452734/en/

Joshua Stahl has been appointed as Chief Executive Officer to guide InterVenn’s next phase of commercial growth. (Photo: Business Wire)

Mr. Stahl has a proven track record of building successful diagnostics companies. In 2013 as the first employee, Mr. Stahl joined ArcherDX, a leading genomics analysis company developing industry-leading products and services for therapy optimization and cancer monitoring. Throughout his tenure, Mr. Stahl held leadership roles with increasing responsibility before becoming Chief Scientific Officer and Chief Operating Officer. He helped build ArcherDX into a leading global diagnostic organization, which was the first to have a Next Generation Sequencing (NGS)-based liquid biopsy companion diagnostic approved by the Pharmaceuticals and Medical Devices Agency. In 2020, ArcherDX was acquired by Invitae Corporation where Mr. Stahl served as President of Oncology following the acquisition.

“Josh is one of the few life sciences executives that helped take a diagnostics company on the full journey, from its infancy to large scale patient impact, to an eventual acquisition,” said Jason Myers, Ph.D., Interim President and Board Director at InterVenn. “I worked alongside him at Archer, and know he has the right set of skills and experience to help bring InterVenn’s novel glycoproteomics technologies to patients and clinicians worldwide.”

Mr. Stahl also has a track record of turning successful Research Use Only (RUO) products into cleared/approved In vitro Diagnostics (IVD), which is a skill set that will directly translate to InterVenn as the company makes the transition from research settings into clinical pathways.

“InterVenn’s technology has strong potential to transform early disease detection and inform medical experts making treatment decisions for patients with life-altering disease,” said Mr. Stahl. “I am excited to lead InterVenn through its next phase of growth and to drive market adoption of our groundbreaking glycoproteomics-based products.”

“Josh is an accomplished leader with the experience to lead InterVenn during this transformative time for the company,” said Jenny Rooke, Ph.D., Founder and Managing Director of Genoa Ventures and Chair of InterVenn’s Board of Directors. “I am thrilled to welcome Josh and work closely with him and the rest of the leadership team to revolutionize early cancer detection and eventually improve patient outcomes with this powerful technology.”

To learn more about InterVenn, please visit https://intervenn.com/.

About InterVenn Biosciences

InterVenn Biosciences decodes the human glycoproteome as a rich source of biological insight, to advance personalized, predictive, and preventative care. InterVenn has pioneered a proprietary technology platform, GlycoVision™, to tap into this layer of biology through AI and ML at a clinically meaningful scale. InterVenn has become a key partner to patients, physicians, researchers, and biopharma organizations navigating the frontier of glycoproteins and their relevance in human health and disease. InterVenn’s glycoproteomic insights help inform decisions about disease detection, treatment strategies, and research priorities. For more information about InterVenn, visit www.intervenn.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230927452734/en/